lucitanib
Lucitanib (INN) is a drug that is being investigated by Clovis Oncology in clinical trials for the treatment of advanced solid tumours including metastatic breast cancer. It is a protein kinase inhibitor that blocks the VEGF receptors 1, 2 and 3, as well as the fibroblast growth factor receptors 1 and 2, and the platelet-derived growth factor receptors alpha and beta. — Wikipedia
Clinical trial activity
11 trials · 15 clinical orgs · 0 marketing orgs
Earliest trial started Jul 1, 2010 (NCT01283945)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1
- Genital Neoplasms, Female · Phase 1/Phase 2
- Lung Neoplasms · Phase 2
- Neoplasms · Phase 2
- Ovarian Neoplasms · Phase 1/Phase 2
- Small Cell Lung Carcinoma · Phase 2/Phase 3
- Triple Negative Breast Neoplasms · Phase 2
Mechanism of action
- Fibroblast growth factor receptor 1INHIBITOR
FGFR1 inhibitor
E-3810 is an ambiguous research code for this compouynd, also research code for rabeprazole, a proton pump inhibitor.
- Fibroblast growth factor receptor 2INHIBITOR
FGFR2 inhibitor
E-3810 is an ambiguous research code for this compouynd, also research code for rabeprazole, a proton pump inhibitor.
Vascular endothelial growth factor receptor inhibitor
E-3810 is an ambiguous research code for this compouynd, also research code for rabeprazole, a proton pump inhibitor.
Chemistry & pharmacology
SMILES
COCCCOc1ccnc(C[S+]([O-])c2nc3ccccc3[n-]2)c1C.[Na+]- Mol. weight
- 381.43 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- WikipediaLucitanib ↗
- ChEMBLCHEMBL2220486 ↗
- ChEMBLCHEMBL1200930 ↗
Also known as
- al3810
- al-3810
- al-3810
- co-3810
- co-3810
- e-3810
- e-3810
- e-3810
- lucitanib
- lucitanib
- lucitanib
- lucitanib
- lucitanib
- s-80881
- s-80881
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04151563 | Phase 1/Phase 2 (Phase 2) | Dec 17, 2019 | Bristol-Myers Squibb, Clovis Oncology, Eli Lilly, Exelixis |
| NCT04254471 | Phase 2/Phase 3 (Phase 3) | Nov 14, 2019 | ShangHai HaiHe Pharmaceutical |
| NCT04042116 | Phase 1/Phase 2 (Phase 2) | Jul 29, 2019 | Bristol-Myers Squibb, Clovis Oncology, European Network for Gynaecological Oncological Trial, Tennessee Oncology, PLLC |
| NCT03992131 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2019 | Clovis Oncology, Immunomedics |
| NCT03260179 | Phase 1 | Aug 31, 2017 | Chinese Academy of Medical Sciences, ShangHai HaiHe Pharmaceutical |
| NCT02747797 | Phase 2 | Apr 1, 2017 | Clovis Oncology, University of California, San Diego |
| NCT02202746 | Phase 2 | Jul 1, 2014 | Clovis Oncology |
| NCT02109016 | Phase 2 | Apr 1, 2014 | Clovis Oncology |
| NCT03117101 | Phase 1 | Mar 1, 2014 | Chinese Academy of Medical Sciences, Fudan University, ShangHai HaiHe Pharmaceutical |
| NCT02053636 | Phase 2 | Dec 1, 2013 | Institut Gustave Roussy, Servier, Universidad Autonoma de Barcelona, University of Milan |
| NCT01283945 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2010 | Servier |
Organizations
Research & Development (15)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clovis Oncology | For profit | 6 | 4 | 1 | 2014 |
| ShangHai HaiHe Pharmaceutical | For profit | 3 | 3 | 2 | 2014 |
| Bristol-Myers Squibb | For profit | 2 | 1 | 1 | 2019 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 2 | 0 | 1 | 2014 |
| Servier | For profit | 2 | 2 | 1 | 2010 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2019 |
| European Network for Gynaecological Oncological Trial | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Exelixis | For profit | 1 | 0 | 1 | 2019 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Immunomedics | For profit | 1 | 0 | 1 | 2019 |
| Institut Gustave Roussy | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Tennessee Oncology, PLLC | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Universidad Autonoma de Barcelona | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of California, San Diego | Academic/Hospital | 1 | 1 | 1 | 2017 |
| University of Milan | Academic/Hospital | 1 | 0 | 1 | 2013 |